Drug Trial Radar · NCT07511010
Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Sep 10, 2026
Primary completion
Oct 22, 2026
Study completion Oct 25, 2026
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants. The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
Chiglitazar/Metformin extended-release tablets under fasting conditionsDrug
a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions
Chiglitazar/Metformin extended-release tablets after a high-fat mealDrug
a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal
multiple-dose of Chiglitazar/Metformin extended-release tabletsDrug
a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10
Primary outcomes
What the sponsor says the trial is designed to measure.
- FE Study: Maximum plasma concentration (Cmax)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- FE Study: Area Under the Plasma Concentration-Time Curve (AUC)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- FE Study: Time to Maximum Plasma Concentration(Tmax)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- FE Study: Elimination Half-life (t1/2)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- FE Study: Apparent Total Clearance (CL/F)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- FE Study: Apparent Volume of Distribution during the terminal phase (Vz/F)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
- Multiple-dose PK study: Maximum plasma concentration (Cmax)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: Area Under the Plasma Concentration-Time Curve (AUC)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: Time to Maximum Plasma Concentration(Tmax)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: steady-state peak concentration (Cmax,ss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: steady-state time to peak concentration (Tmax,ss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: under the plasma concentration-time curve at steady state (AUCss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: trough concentration (Ctrough)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
- Multiple-dose PK Study: accumulation ratio (Rac)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.